On This Day in Health: June 9, 2025
On June 9, 2025, the U.S. Food and Drug Administration approved Enflonsia, Merck's long-acting antibody for preventing respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season. Merck announced the decision from Rahway, New Jersey. The medicine, clesrovimab-cfor, added another preventive option against a virus that can cause serious breathing illness early in life. Its authorized regimen used the same 105-milligram dose regardless of an infant's weight. The decision was a regulatory milestone in infant protection, while recommendations and preparations for use in the coming RSV season remained separate implementation steps.
RSV can infect the airways and lungs, causing conditions such as bronchiolitis and pneumonia. Very young infants can become seriously ill, creating a need for protection before exposure leads to disease. Enflonsia works through passive immunization: it supplies a ready-made monoclonal antibody rather than asking an infant's immune system to build its own response to a vaccine. The antibody targets the virus's fusion protein, helping block its entry into cells. Its extended duration was designed to cover approximately five months, a typical RSV season. It was not the first antibody approach to RSV prevention; earlier options had already established that supplying protective antibodies could help vulnerable infants.
The FDA reviewed evidence from two clinical trials. One, known as CLEVER or Trial 004, compared a single injection with placebo in preterm and full-term infants across 22 countries. It assessed medically attended RSV lower respiratory illness and more severe outcomes during the months after dosing. A second study, SMART or Trial 007, examined infants at increased risk and used palivizumab as the comparison treatment. These were distinct study designs addressing related questions, rather than one uniform trial in every infant group. Together they supported authorization of a preventive medicine for the first season, with the expected benefit focused on reducing RSV disease rather than guaranteeing that no infection could occur.
The June approval also came with practical and clinical limits. Enflonsia was an injection administered by a healthcare professional, and it was intended for prevention rather than treatment of an RSV infection already underway. Injection-site redness, swelling and rash were among the reported adverse reactions, and serious allergy considerations appeared in the labeling. Authorization alone could not determine whether every eligible family would have timely access before seasonal circulation. Its historical significance was the addition of another long-acting option with a consistent dose across infant weights. The event reflects a broader shift toward protecting infants before their first encounter with RSV, using antibody engineering alongside the organizational work needed to deliver prevention at the right time.
Passive immunization provides an antibody directly. This differs from vaccination, which stimulates a person's immune system to develop a response.
RSV can cause bronchiolitis and pneumonia in infants, making prevention before the first seasonal exposure an important objective.
The authorized medicine used a single 105-milligram dose independent of weight for infants born during or entering their first RSV season.
Protection was not absolute, and the medicine was not an RSV treatment. Clinical labeling included injection reactions and allergy precautions.
The approval joined an existing history of antibody prevention, including palivizumab, rather than introducing the first RSV preventive intervention.
A regulatory decision and a successful seasonal program are different achievements; distribution and timely access remain necessary to realize a medicine's benefit.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.